ArticleSleep & breathing = Schlaf & Atmung2025
Risk of hyperlactatemia in patients with obstructive sleep apnea receiving metformin: a cross-sectional study.
Article in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early dynamic glucose dysregulation in obese adolescents with obstructive sleep apnea: a comparative analysis with fasting lactate.Journal of endocrinological investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeType 2 diabetes is a common comorbidity in individuals with obstructive sleep apnea (OSA). Metformin, one of the most commonly applied therapy options for type 2 diabetes, is known to increase lactate production. Given that OSA may put patients at risk of hyperlactatemia, it is important to examine lactate levels in patients receiving metformin. This study aimed to identify factors affecting lactate concentrations and the consequent risk of hyperlactatemia in this population.
methodsA total of 505 patients were included in the study. All underwent a detailed and systematic clinical evaluation and attended diagnostic nocturnal polysomnography. Serum lactate levels were measured at a single time point.
resultsMedian lactate concentration across the cohort was 1.0 mmol/L and did not differ by OSA severity (p = 0.82). 18.8% of patients used metformin and exhibited higher lactate concentrations compared to those not receiving the medication (p < 0.001). Elevated lactate levels (> 0.8 mmol/L) were detected in 64.8% of patients. Patients with increased lactate levels were more often active smokers. Multivariable analysis revealed that hyperlactatemia was associated with metformin use (p < 0.001) and active smoking (p = 0.014).
conclusionOur findings indicate that metformin use in patients with OSA and type 2 diabetes appears to be safe for lactate metabolism, regardless of OSA severity. However, the risk of hyperlactatemia increases in actively smoking patients treated with metformin, which calls for targeted interventions to encourage smoking cessation in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.